segal cv 18 - biology.ucdavis.edu · the major goal of this project is to develop a therapy for...

1

CURRICULUM VITAE PERSONAL: Name: David Jay Segal Address: Genome Center Department of Biochemistry and Molecular Medicine University of California, Davis 4512 GBSF 451 Health Sciences Dr. Davis, CA 95616 Telephone: 530-754-9134 FAX: 530-754-9658 Email: [email protected] EDUCATION: Post-Doctoral 2002 The Scripps Research Inst, La Jolla, CA Molecular Biology Ph.D. 1996 University of Utah, Salt Lake City, UT Biochemistry B.S. (honors) 1989 Cornell University, Ithaca, NY Biology PROFESSIONAL EXPERIENCE: 2014-present Professor, Genome Center, Biochemistry and Molecular Medicine,

Pharmacology, and the M.I.N.D. Institute, University of California, Davis, CA. 2013-2014 Associate Professor, M.I.N.D. Institute, University of California, Davis, CA. 2013-present Adjunct Without Salary, Texas A&M University, TX. 2011-2015 Associate Director of Genomics for the UC Davis Genome Center. 2010-2014 Associate Professor, Dept. of Biochemistry and Molecular Medicine, School of

Medicine. University of California, Davis, CA. 2008-2010 Associate Professor, Genome Center and Dept. of Pharmacology, School of

Medicine. University of California, Davis, CA. 2005-2008 Assistant Professor, Genome Center and Dept. of Pharmacology, School of

Medicine. University of California, Davis, CA. 2002-2005 Assistant Professor, Dept. of Pharmacology and Toxicology, College of

Pharmacy. University of Arizona, Tucson, AZ. PROFESSIONAL MEMBERSHIPS: 2016-present American Society for Gene and Cell Therapy 2018-present, member, Neurologic & Ophthalmic Gene & Cell Therapy Cmt 2013-2014 International Association of Medical Science Educators 2013-2014 American Association for the Advancement of Science 2012-2014 International Society for Stem Cell Research 2011-2014 American Society for Human Genetics 2005-2011 American Society for Gene and Cell Therapy 2005-2007 Protein Society 2006-2008 Zinc Finger Consortium CURRENT RESEARCH ACTIVITIES: Specific research foci in the Segal Lab revolve around engineering custom DNA-binding proteins for the following applications: • Gene therapy: Molecular Therapy for Angelman and Prader-Willi Syndromes • Zinc finger, TALE, and CRISPR/Cas programmable DNA binding systems: targeted nucleases, epigenetic modifiers, transposases, transcription factors. • Genetic variation and diseases: Genome Engineering to study SNP and enhancer functions

Segal, D.J. Curriculum Vita 2

RESEARCH SUPPORT: Active: Research Award (Segal) 04/01/18 – 03/31/20 0.2 cal months Innovative Genomics Institute, UC Berkeley $225,000 ADC “Detecting gene and epigenetic edits in live cells” The major goal of this project is to develop “turn-on” sensors of DNA sequence that function in living cells. R21 HG009742(Farnham) 10/01/17 – 09/30/19 1.2 cal months NIH-NCI $156,140 ADC “Development of a novel promoter tagging technology to identify enhancer targets” The major goal of this project is to develop methods for identifying topologically associated domains that are not based on a chromosomal conformation capture method. W81XWH-17-1-0200 (Segal) 06/01/17 – 11/31/18 0.6 cal months DOD-CDMRP $93,288 ADC “Methylated Mouse Model of Fragile X” The major goal of this project is to develop a transgenic system that could methylate the FMR1 locus in a mouse model of Fragile X, and targetable demethylases as a therapeutic approach. DISC2-09032 (Segal, Fink) 12/01/16 – 11/30/18 2.4 cal months California Institute for Regenerative Medicine $346,000 ADC ($121,580 ADC to Segal) “MSC delivery of an artificial transcription factor to the brain as a treatment for Angelman Syndrome” The major goal of this project is to use MSCs to deliver an artificial transcription factor into the brain of a mouse model of Angelman Syndrome. FAST-Track Grant (Anderson) 10/15/16 – 10/14/18 0.6 cal months Found. Angelman Syndrome Therapeutics $250,000 ADC ($35,000 to Segal) “Expression of UBE3A via lentivector delivery in blood cells to treat Angelman Syndrome” The major goal of this project is to develop a therapy for Angelman Syndrome based on hematopoietic stem cells reprogramed to express UBE3A. R21 CA204563 (Segal) 07/01/16 – 06/30/18 1.2 cal months NIH-NCI $ 258,500 ADC ($100,000 ADC to Segal) “CRISPR-based epigenetic modifiers” The major goal of this project is to engineer a toolbox of easy-to-use, highly specific and targetable modifying factors that can manipulate the epigenome in a predictable manner. R21 CA204563 Diversity Supplement (Segal) 04/01/17 – 06/30/18 0.2 cal months NIH-NCI $ 45,485 ADC “Supplement to CRISPR-based epigenetic modifiers” This funding would support an under-represented minority graduate student on this project. DP160104106 (Mackay) 02/01/16 – 01/31/20 0.2 cal months Australian Research Council AU$111,200 ADC (AU$25,000 ADC to Segal) “The design of targetable epigenetic modifiers” The goal of this project is to create split-enzyme epigenetic modifying proteins. Consortium Grant (Weeber) 05/01/13 – 04/30/19 1.2 cal months Found. Angelman Syndrome Therapeutics $2,642,618 ADC ($445,101 ADC to Segal) “FAST Integrative Research Environment (FIRE) Initiative”


The major goal of this project is to develop innovative therapies for Angelman Syndrome. Pending: R21 (Tarantal, Segal) 09/01/18 – 08/31/20 0.24 cal months NIH-ORIP $137,500 ADC “Precision Nonhuman Primate Models for Congenital Diseases” The major goal of this project is to use a new approach to develop new preclinical models of human disease using gene editing. EFRI2018 (Segal, Brady, Savageau) 07/01/18 – 06/30/22 1.2 cal months NSF $500,000 ADC “EFRI CEE: Engineering plant traits by controlling transgenerational epigenetic inheritance” The major goal of this project is to engineer long-term, multi-generational control of epigenetic information and gene expression in plants. R21 (Seo, Ferrara) 07/01/18 – 06/30/20 1.2 cal months NIH $137,500 ADC “Molecular imaging of the kinetics of brain-targeted therapeutics” The major goal of this project is study modified capsids of AAV in animals using PET imaging. UCD-Israel Collab Grant (Segal, Shabat) 07/01/18 – 09/30/20 0.2 cal months UC Davis $25,000 total costs “Better Genome Editing through Chemistry” The major goal of this project is travel exchanges to facilitate DNA probe and substrate designs. UCD-USyd Collab Grant (Segal, Mackay) 03/01/18 – 12/31/19 0.2 cal months University of Sydney AU$40,000 total costs “New technologies for epigenome and transcriptome editing” The major goal of this project is travel exchanges to facilitate chromatin and inhibitor studies. RM1 04/01/19 – 03/31/24 0.24 cal months (Tarantal, Segal, Hartigan-O’Connor, Sullenger) NIH-NIGMS $250,000 ADC “Diagnosis and Mapping of Inflammation for Improved Health Outcomes” The major goal of this project is to study chronic and surgical inflammation, and to create modulators of DAMPs that can improve health outcomes. R21 (Segal) 09/01/18 – 08/31/20 1.2 cal months NIH-NIMH $125,000 ADC “A toolkit for targeted epitranscriptomics in the brain” The major goal of this project is to create targeted writers and erasers of m6A on mRNA. U54CA233306 (Pan) 09/01/18 - 08/31/23 1.2 cal months NIH-NCI $lots “University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities” The major goal of this project is to use CRISPR to test the function of patient-derived SNVs. EAGER (Brady, Patron, Segal) 07/01/18 – 06/30/20 1.2 cal months NSF $207,271 ADC “Engineering complex traits using targeted, multiplexed genetic and epigenetic mutagenesis”


The major goal of this project is the genetic and epigenetic engineering of complex traits in plants. R21 (O’Geen) 09/01/18 – 08/31/20 0.24 cal months NIH-NCI $142,426 ADC “Determinants of Persistence in Epigenetic Editing” The major goal of this project is to use screening methods to identify cellular factors that contribute to the persistence of epigenetic gene repression. UG3/UH3 (Lam,Cheng) 09/01/18 – 08/31/23 0.6 cal months NIH-NCATS $700,000 ADC “Cell-specific nanocarrier with endocytic and endosomolytic activities for therapeutic genome editing” The major goal of this project is to develop novel nanoplatforms for efficient in vivo delivery of genome editing machinery into specific cell types. R21 (Tarantal, Segal, Fink) 09/01/18 – 08/31/23 1.8 cal months NIH-NCATS $700,000 ADC “Innovative Technology for Genome Editing Delivery” The major goal of this project is to develop gene editing for targeted somatic cells based on their internal genetic regulatory environment, particularly microRNA (miRNA) expression. Completed: Small Grant (Segal) 2002-2003 0.2 cal months U. Arizona Faculty Small Grants Program $10,000 "Inactivation of HIV by in vivo genetic modification" The major goal of this project was to permanently disrupt the integrated proviral HIV genome using engineered zinc finger nucleases. IRG-110T (Segal) 2002-2003 0.2 cal months American Cancer Society $10,000 "Detecting genetic variations in a living cell using SEIER (SEquence-Induced Enzyme Reactivation)" The major goal of this project was the development of split reporter-zinc finger fusion proteins that will generate a signal in the presence of mutated DNA sequences involved in cancer. R21 CA10365 (Segal) 2003-2007 1.2 cal months NIH-NCI $100,000 "Inactivation of HIV by in vivo genetic modification" The major goal of this project was to permanently disrupt the integrated proviral HIV genome using engineered zinc finger nucleases. Pilot Grant (Segal) 2004-2005 0.2 cal months UA SWEHSC (NIH P30ES06694) $17,500 “Biochemical and Bioinformatics Studies on Uranium Toxicity of Zinc Fingers” The major goal of this project was to study the protein-protein interactions mediated by natural zinc finger motifs. Contract 9016 (Segal) 2004-2005 0.2 cal months Arizona Disease Control Res Committee $40,610 “Protein Interactions Mediated by Cys2-His2 Zinc Finger Domains”


The major goal of this project was to study the protein-protein interactions mediated by natural zinc finger motifs. SPORE in GI Cancers (Segal) 2005-2005 0.2 cal months Developmental Research Program Grant $39,750 (Funded through P50 CA95060, PI: Gerner) "SEER - a novel method for visualizing mutations" The major goal of this project was the development of split reporter-zinc finger fusion proteins that will generate a signal in the presence of mutated DNA sequences involved in cancer. R21 CA122630 (Ghosh) 2006-2008 0.6 cal months NIH-NCI $128,822 ($64,411 to Segal) Score: 139, Percentile Rank: 0.0 "Direct Detection of Hypermethylation in Cancer" The major goal of this project was the development of split reporter-zinc finger fusion proteins that will generate a signal in the presence of methylated DNA sequence. Pilot Grant (Segal) 2007-2008 0.2 cal months California Research Center for the Biology of HIV in Minorities $29,536 “Imaging Latent HIV Infection on a Per-Cell Basis” The major goal of this project was the development of beta-lactamase/zinc finger fusion proteins that will generate a fluorescent signal in the presence of a HIV DNA sequence. Pilot and Collaborative Grant (Segal) 04/01/09 – 06/30/10 0.2 cal months UC Davis Clinical and Translational $30,000 Science Center (NIH UL1RR024146) “Epigenetic therapy for Rett syndrome” The major goal of this project was to develop zinc finger-based artificial transcription factors that can activate expression of the MECP2 gene in a female neural cell line. New Research Initiative Grant (Segal) 07/01/09 – 06/30/10 0.2 cal months UC Davis Academic Senate $12,000 “Methods for Genome Engineering” The major goal of this project was to obtain preliminary data for a competitive R01 proposal to investigate the feasibility of engineering coronary artery disease haplotypes using zinc finger nucleases. Exploratory project (Revzin) 11/01/08 - 10/31/10 1.2 cal months UC Davis-LLNL POC Technologies Center $150,000 ADC ($56,000 to Segal) (NIH-NIBIB U54EB007959) "A Novel Microdevice Employing Protein Microarrays for Multiplexed Detection of Pathogens in Blood” The major goal of this project was to develop a lab-on-a-chip device that can separate pathogens from blood, capture specific agents, then use the presence of specific DNA sequences to produce a visual signal. Pilot Grant (Segal) 11/01/09 – 10/30/10 0.2 cal months UC Davis Genome Center $10,000 “Custom nucleases using TAL-effector domains” The major goal of this project was to investigate the feasibility of using engineered TAL-effector DNA-binding proteins to create targetable nucleases.


Research Grant (Segal) 01/01/09 - 12/31/10 1.2 cal months Angelman Syndrome Foundation, $76,055 "Towards gene therapy for Angelman Syndrome using Artificial Transcription Factors" The major goal of this project was to develop zinc finger-based artificial transcription factors that can activate expression of the Ube3a gene in mouse neural cell lines. R01 GM077403 (Segal) 05/01/06 - 04/30/11 1.2 cal months NIH-NIGMS $231,423 ADC "SEER - a novel method for visualizing mutations" The major goal of this project was the development of beta-lactamase/zinc finger fusion proteins that will generate a fluorescent signal in the presence of a specific DNA sequence. Highly Innovative Pilot Project Award (Segal) 01/01/11 – 06/30/11 0.2 cal months UC Davis Clinical and Translational Science Center $25,000 “Genetic modification of primary patient fibroblasts” The major goal of this project is to mutate specific SNPs involved coronary artery disease using zinc finger and TAL nucleases, and evaluate the potential of the modified cells to form iPSCs. Pilot Grant (Segal) 01/01/11 – 12/31/11 0.2 cal months UC Davis Genome Center $25,000 “Rapid Assembly of TAL-effector domains” The major goal of this project is to develop enabling technology in the UC Davis Genome Center using engineered TAL-effector DNA-binding proteins researchers on campus. HeART Grant (Segal) 01/01/11 – 12/31/11 0.2 cal months International Rett Syndrome Foundation $44,913 “Epigenetic therapy for Rett syndrome” The major goal of this project is to advance the development of a potential gene therapy for Rett syndrome using zinc finger based artificial transcription factors to activate the epigenetically silenced MECP2 allele. Pilot Funding (Segal) 09/01/10 – 08/31/12 0.2 cal months Northwest Genome Engineering Consortium $50,000 ADC “In vivo directed evolution of tools for genome engineering” The major goal of this project is to develop a relatively simple yet robust method of directed evolution that can help to realize the full potential of molecular tools for genome R21 NS071028 (Segal) 09/15/10 - 08/14/12 2.4 cal months NIH-NINDS $138,000 ADC "Towards Gene Therapy for Angelman Syndrome" The major goal of this project is to activate the epigenetically silenced paternal Ube3a allele using a zinc finger-based artificial transcription factor (ATF) in a mouse model of AS. Highly Innovative Pilot Project Award (Rogers) 01/01/12 – 12/31/12 0.2 cal months UC Davis Clinical and Translational Science Center $50,000 (no funds to Segal) “Ex Vivo Analysis of Human Coronary Artery Plaque Endothelium: Development of a Novel Diagnostic Tool” The major goal of this project is to gain a detailed understanding of the pathways leading to enhanced inflammation in CAD and assess biomarkers that could predict myocardial infarction. Application ID 632757 (Mackay) 02/11/10 – 02/10/13 0.2 cal months National Health and Medical Research Council, Australia $187,891 ADC (no funds to Segal) “Designer RNA-binding proteins for research and therapeutic purposes”


The major goal of this project is to develop engineered sequence-specific single-stranded RNA binding proteins. Research Project Award (Segal) 04/01/12 – 03/31/13 0.2 cal months Foundation for Prader-Willi Research $48,482 DC “Reactivation of maternally-silenced genes in PWS” The major goal of this project is to develop artificial transcription factors that can reactivate the maternally-silenced genes in a mouse model of PWS. R01 GM083158 (Moisyadi) 07/01/08 - 06/30/13 1.2 cal months NIH-NIGMS $206,310 ADC ($62,091 to Segal) “Transposon based Mammalian Transgenesis and Transfection” The major goal of this project is the development of zinc finger-targeted transposons for gene therapy. R21 HG006761 (Farnham) 04/01/12 - 03/31/14 1.2 cal months NIH-NHGRI $138,000 ADC ($13,856 to Segal) "Development of a Nuclease-mediated Technology to Validate Chromatin Hubs" The major goal of this project is to use custom nucleases to delete chromatin hubs in order to probe their function in regulating gene expression. Phase I Round 8 Grand Challenge Explorations (Segal) 05/01/12 – 04/30/14 0.2 cal months Bill and Melinda Gates Foundation $100,000 DC “Transcription factor screening for P. falciparum therapy” The major goal of this project is to take advantage of a recently discovered protein framework to develop next gen drug-like proteins that will target malaria on a genetic level. W81XWH-13-1-0101 (Segal) 06/01/13 – 5/31/14 0.6 cal months DOD CDMRP NF Res Program $100,000 ADC “Gene Therapy for Childhood Neurofibromatosis” The major goal of this project is to develop an innovative gene therapy for neurofibromatosis involving TALE transcription factors and tumor-targeting bacteria in mouse cell culture. Application ID 1030830 (Mackay) 02/11/12 – 02/10/15 0.2 cal months National Health and Medical Research Council, Australia $187,891 ADC (no funds to Segal) “Designer DNA-Binding Proteins Targeting Methylated DNA For Research And Therapeutic Purposes” The major goal of this project is to develop engineered sequence-specific proteins that can bind specifically to methylated DNA. R01 GM097073 (Segal) 04/01/11 – 03/31/15 2.4 cal months NIH-NIGMS $190,000 ADC “NextGen DNA Binding Proteins Based on TAL Domains” Priority Score 20, Percentile 10 The major goal of this project is to investigate the structure of TAL-effector domains and their potential as a scaffold for engineering new DNA-binding proteins. Highly Innovative Pilot Project Award (Segal) 07/01/14 – 06/30/15 0.2 cal months UC Davis Clinical and Translational Science Ctr $50,000 ADC “Engineering Teratomas – a Paradigm Shift for Biomedical Genomics” The major goal of this project is to determine if eQTLs can be studied in multiple cell lineages by examining genetically engineered taratomas by single-cell RNA-seq analysis.


New Research Initiative Grant (Ross) 07/01/14 – 06/30/15 0.2 cal months UC Davis Academic Senate $23,952 ADC (no funds to Segal) “Generation of pig models for human disease” The major goal of this project is to generate an APC gene knockout in pigs using CRISPR nucleases as a model of colorectal cancer. Award 201401674 (Segal) 07/01/14 – 06/30/15 0.6 cal months Foundation for Prader-Willi Research $70,000 ADC “Injectable protein-based gene activation therapy for PWS” The major goal of this project is to develop artificial transcription factors that activate the silenced maternal Snord116 and Magel2 genes in a mouse model. Medical Research Grant (Segal) 07/01/11 – 06/30/15 0.8 cal months WM Keck Foundation $250,000 ADC “Probing the Genetic Architecture of Common Diseases” The major goal of this project is to develop a robust method to mutate and probe the function of individual genetic variants in disease-relevant cell types. Faculty Research Grant (Segal) 07/01/15 – 06/30/16 0.2 cal months UC Davis Academic Senate $23,973 “Bacterial Argonautes – the Next Gen of Genome Editing” The major goal of this project is to investigate the utility of what might be a next generation of targetable nuclease, prokaryotic Argonautes. Pilot Grant (Segal) 07/01/15 – 12/31/16 NCE 0.2 cal months UC Davis IDDRC $30,000 “Injectable Regulators of ASD-relevant Genes” The major goal of this project is to investigate the use artificial transcription factors in the Rodent Behavioral Core to alter the expression of Shank3 in the brains of mice and rats. Project Grant 1063188 (Mackay) 02/11/14 – 02/10/17 0.2 cal months National Health & Medical Research Council, Australia AU$226,667 ADC (AU$15,000 to Segal) “Do transcription factor-RNA interactions represent a new mechanism of gene regulation?” The major goal of this project is to investigate the hypothesis that many known DNA-binding proteins also bind to RNA. CDKL5-16-107-01 (Nolta) 05/01/16 – 04/30/17 0.6 cal months CDKL5 Pilot Grant Program $ 150,000 ($9,000 to Segal) “Development of TALE and CRISPR/Cas9 as a putative therapy for treatment or correction of genetically linked CDKL5 Deficiency” The major goal of this project is to development of TALE and CRISPR/Cas9 as a putative therapy for treatment or correction of genetically linked CDKL5 Deficiency. Grant-In-Aid (Mackay) 04/01/15 – 12/31/17 0.2 cal months Found. Angelman Syndrome Therapeutics-AU AU$284,000 (no funding to Segal) “RNA binding motifs as therapeutic targets for Angelman Syndrome” The major goal of this project is to discover potential regions of RNA-protein interaction in the Ube3a-ATS that can be inhibited to reactivate Ube3a expression. PROFESSIONAL ACTIVITIES AND SERVICE: Policy Service:


2015 Advocate for Rare Disease Research with Bill Shorten, leader of the national opposition party (Labor) of Australia.

2013 Workshop participant, "Examining the Oversight Issues of Plant Targeted Genetic Modification (TagMo)", University of Minnesota

2012-2013 Advocate against California SB 222 Genetic Privacy Act by State Senator Alex Padilla, with UC Office of the President Legislative Director.

Journal Editorial Board and Reviewer: 2016-present Editorial Board member, Journal of Biological Chemistry (2017 IF 4.8) 2016-present Editorial Board member, Nucleic Acids Research (2017 Impact Factor 10) 2014-present Editorial Board member, Genome Research (2017 Impact Factor 12) 2002-present Ad hoc manuscript reviewer for: Accounts of Chemical Research, Biochemistry,

Biochemistry and Cell Biology, Bioorg Med Chem Let, BMC Bioinformatics, Briefings in Functional Genomics, Chem Res Tox, eLife, J. Am. Chem. Soc., J. Biotechnology, J Clin Investigation, J. Medicinal Chemistry, J. Molec. Biol., Molecular Therapy, Nature, Nature Biotechnology, Nature Methods, Nature Reviews Genetics, Neuromuscular Disorders, Nucleic Acids Research, Proc Natl Acad Sci USA, Science, Theoretical Biology and Medical Modeling, Trends in Biotechnology.

Grant Study Section and Reviewer: 2017 Abu Dhabi Educational Council, Award for Research Excellence (AARE) 2017 NIH Special Emphasis Panel 2017/05 ZAI1 CB-A 2017 NIH Special Emphasis Panel 2017/05 ZRG1 BCMB-A 2017 NIH 2017/05 GDD Gene and Drug Delivery Systems Study Section 2015 Abu Dhabi Educational Council, Award for Research Excellence (AARE) 2015 NIH AIDS Discovery and Development of Therapeutics 2016/01 ADDT 2014 NIH Recombinant DNA Advisory Committee (RAC) 139 MEETING 2014 NHLBI Progenitor Cell Biology Consortium - Pilot Studies 2013 NIH Special Emphasis Panel 2013/10 ZRG1 ADDT-K 2013 NIH Special Emphasis Panel 2013/05 ZHL1 CSR-K 2012 NIH Special Emphasis Panel 2012/ ZRG1 IMST-J 2010 NIH Special Emphasis Panelp 2010/08 ZRG1 GGG-F 2009 NIH Special Emphasis Panel 2009/10 ZRG1 GGG-F 2009 NIH Special Emphasis Panel 2009/10 ZRG1 GGG-A 2004-present Ad hoc grant reviewer for: Association Françasi contre les Myopathies, Bill and

Melinda Gates Foundation, Binational Science Foundation of United State-Israel, European Research Council (ERC), Foundation for Angelman Syndrome Therapeutics, Foundation for Prader-Willi Research, National Centre for the Replacement, Refinement and Reduction of Animals in Research-UK, National Institutes of Health (NIH), National Science Foundation (NSF), North Carolina Biotechnology Center, Pitt-Hopkins Research Foundation, Samsung Corporation, Telethon Italia, The Wellcome Trust

University Training Grant Affiliation Service 2014-present Trainer, Training Program in Chemical Biology (T32 CM113770) 2013-present Trainer, Translational Training Program in Basic and Cardiovascular Sciences

(T32 HL086350). 2012-present Trainer, Interdisciplinary Training for Autism Researchers (T32 MH073124) 2009-present Trainer, Oncogenic Signals and Chromosome Biology Training Program

(T32 CA108459). 2008-2015 Trainer, Integrating Medicine into Basic Science (HHMI 56006769) 2007-present Trainer, Pharmacology Training: Bench to Bedside (T32 GM099608) 2007-2012 Executive Committee, Training Program in Biomolecular Technology


2007-2017 Trainer, Training Program in Biomolecular Technology (T32 GM008799) 2006-present Trainer, Molecular and Cellular Biology Training Program (T32 GM007377) University Faculty Search Committee Service 2014-15 Co-Chair, Genome Center/MIND Institute Genomics Faculty Search Committee 2014 Pediatrics Genomic Medicine Faculty Search Committee 2014 Genome Center Sequencing Core Manager Search Committee 2013-14 Chair, Genome Center/MIND Institute Genomics Faculty Search Committee 2011 Biochemistry and Molecular Medicine Faculty Search Committee 2010-2012 Genome Center Faculty Search Committee 2010 Genome Center Sequencing Core Manager Search Committee 2010 Genome Center Sequencing Core Research Scientist Search Committee 2012-present Faculty Mentor for Luis Carvajal-Carmona, Justin Siegel, Megan Dennis,

Fereydoun Hormozdiari University Other Committee Service • University of California, Davis 2018 Chair, Review Task Force for Pharmaceutical Chemistry Masters program 2016-2019 Member, Committee for Research Affairs, SOM 2014 BGI@UCD Associate Director Search Committee 2013-present Chair, Educational Policy, Integrative Genetics and Genomics Graduate Group 2013-2015 Organizer, monthly Human Genetics and Genomics Focus Group 2013 Member, Endowed Chair ad hoc review committee 2013-2015 Member, Early Life Human Genomics faculty group 2011-2012 Organizer, biweekly Omics Office Hour sessions at UCD and UCDHS 2011 BGI@UC Davis Human and Animal Health and Wellness Faculty Workgroup 2011 Human Genetics and Genomics White Paper Committee 2010-2015 Organizer, monthly Epigenomics Focus Group 2010-2015 Organizer, biweekly Genome Center Faculty Seminar Series 2010-2012 Kuali Research Administration System Oversight Committee 2009-2012 Chair, Institutional Biosafety Committee, UC Davis campus 2009-2012 Safety Chairs Committee 2009-2012 Containment Laboratory Review Committee 2008-2014 Member, SOM Block Council 2007-2012 Biological Safety Administration Advisory Committee, UC Davis campus 2007-2010 Admissions Committee, BMB graduate group 2007-2009 Regent’s Scholarship Administrative Advisory Committee, UC Davis campus 2006 Pharmacology Chair Search Committee 2005-present Genome Center Operations Committee • University of Arizona: 2004 Selection Committee, Undergraduate Biological Research Program 2004 - 2005 Admission Committee, PharmD program 2004 - 2005 Recruitment/Admissions Committee, Biological Chemistry Program 2004 - 2005 Recruitment/Admissions Committee, Medicinal & Natural Products Chemistry 2003 - 2005 Research and Graduate Affairs Committee Scientific Advisory Boards: 2013-2017 Scientific Advisory Board member, Center for Genome Engineering, Institute for

Basic Science, Korea. 2012-present Scientific Advisory Board member, Pitt Hopkins Research Foundation. 2008-present Scientific Advisory Board member, Foundation for Angelman Syndrome

Therapeutics (FAST). Consultant Services: 2014-present Consutant, Glidepoint Global 2001-2003 Consultant, Stell, La Jolla, CA, a biotech company


Outreach Service 2011-present Osher Lifelong Learning Institute, UC Davis Extensions: lectures on Genomics.

(F11, Sp13, F14, Sp17) 2011-2014 Organizer, “Evening with the Genome Center” event at Pence Gallery in Davis

(F11, F12, Sp13, F13, Sp14, F14) TEACHING: I. Professional (M.D. or Pharm.D.) courses • University of California, Davis: MDS 406: Endocrinology, Nutrition, Reproduction and Genetics (ENRG), required 1st year, 17 hours (W14) Epigenetics: Endocrinology Fellows, 1 hour (W14) Pharmacogenomics: Neurosurgery Fellows, 1 hour (W14) BCM 410A: Genetics and Molecular Medicine, required, 1st year, 1 hour (F13) BCM 410A/PED 420: Genetics and Molecular Medicine, required, 1st year, 10 hours (F12) MDS 405: Metabolism, Endocrinology, Reproduction and Nutrition (MERN), required, 1st year, 5 hours (Sp13) BCM 410A: Molecular Medicine, required, 1st year, 4 hours, (F09, F10, F11) PHA 400A: Principles of Pharmacology, required, 1st year curriculum, 2 hours, (W07, W08) PHA 400C: Principles of Pharmacology, required, 2nd year curriculum, 3 hours, (F07, F08) • University of Arizona: PCOL 820-1: Case Studies in Biochemical Pharmacology, 1 unit, required, 4 hours. PCOL 836A: Chemotherapy of Infections Diseases, 3 units, required, 5 hours. PCOL 837B: Medicinal Chemistry III, 2 units, required, 2 hours. PCOL 871A: Pharmacology I, 4 units, required, 3 hours. II. Graduate (Ph.D.) courses • University of California, Davis: GGG 201A: Advanced Genomics Analysis, 5 units, required, 12.5 hours (F14, F15, F16, F17) MCB 211: Macromolecular Structures and Interactions, 3 units, required, 9 hours (F08, F09, F10, F11, F12, F13, F14, F15, F16, F17) PHA/GGG 250: Functional Genomics: From bench to bedside, 3 units, elective, 5 hours (Sp08, Sp10, Sp12, Sp14, Sp16,Sp18) GGG 201C: Molecular Genetic Mechanisms of Disease, 4 units, required, 14 hours (Sp12, Sp13) HHMI-Integrating Medicine into Basic Science – Hot Topics seminar, 2 hour (F11, F12) PHA 225: Gene Therapy, 3 units, elective, 6 hours (Sp11, Sp13) MCB 221C: Molecular Biology, 4 units, required, 2 hours (Sp09) PTX 290 “Meet the Faculty” Seminar Series, 1 unit, 10 hours (F08, F09) • University of Arizona: PCOL 530: Proteins and Nucleic Acids as Drug Targets, 2 units, required, 3 hours. BIOC 595C: Current Topics in Biochemistry and MCB, 1 unit, required, 1 hour. MKTG 579: Marketing of Innovation, 3 units, elective, 3 hours. PCOL 610: Molecular & Cellular Toxicology, 3 units, elective, 2 hours. PHSC 670: Principles in Drug Discovery, Design and Development, 3 units, elective, 3 hours. CHEM 546: Advanced Organic Chemistry, 3 units, elective, 2 hours. PHSC 596H: Current Topics in Pharmaceutical Sciences, 1 unit, elective, 1 hour. PHSC 596C: Advanced Toxicology, 1 unit, elective, 1 hour. III. Undergraduate courses • University of California, Davis: FRS 003: Freshman Seminar: Gene therapy: How genes control you and how you can control

them, 1 unit, elective, 10 hours. (S07, F07, F08, F09, F10, F11, F12, F13, F15, F16, F17)


BIM 140: Protein Engineering, 4 units, elective, 2 hours. (Sp09, F10, F11, F12) BIS 198: Functional Genomics, 3 units, elective, 1.5 hours (Sp11) IV. Outreach courses • University of California, Davis: Genetics Case Conference, UC Davis MIND Institute: 1 lecture on Genomics. 1 hour (F11) College of Nursing, UC Davis: 1 lecture on Genomics. 2 hours (F11) Osher Lifelong Learning Institute, UC Davis Extensions: 4 lectures on Genomics. 4 hours (F11,

Sp13, W18) Nara Institute of Science and Technology (NAIST), Nara, Japan: 3 guest lectures on Genomics,

Disease, and Gene Therapy and 1 research seminar. 4 hours. (W09) California State Summer School for Mathematics and Science (COSMOS): Biotechnology cluster

1. Outreach program for CA high school students. 20 hours. (Su07) V. Courses Coordinated or IOR • University of California, Davis: GGG 201A: Advanced Genomics Analysis, 5 units, required, 50 hours (F14, F15, F16, F17) PHA 250: Functional Genomics: From Bench to Bedside, 3 units, elective, 30 hours (Sp10, Sp12, Sp14, Sp16) MDS 406: Endocrinology, Nutrition, Reproduction and Genetics (ENRG), required 1st year, 80 hours (F14), co-IOR with Judith Turgeon and Melody Hou. BCM 410A/PED 420: Genetics and Molecular Medicine, 2.5 units, required, 51 hours, co-IOR with Colleen Sweeney (F12) GGG 201C: Molecular Genetic Mechanisms of Disease, 4 units, required, 40 hours (Sp12, Sp13) PHA 225: Gene Therapy, 3 units, elective, 30 hours (Sp11, Sp13) FRS 001: Freshman Seminar: Gene therapy: How genes control you and how you can control them, 1 unit, elective, 10 hours. (S07, F07, F08, F09, F10, F11, F12, F13) PHA 400B: Principles of Pharmacology (Block 3), 2.5 units, required, 10 hours (Su08, Su09) PHA 400C: Principles of Pharmacology (Block 4), 2.5 units, required, 10 hours (F07, F08, F09) PHA 400D: Principles of Pharmacology (Block 5), 2.5 units, required, 10 hours (W08, W09) PTX 290 “Meet the Faculty” Seminar Series, 1 unit, 10 hours (F08, F09) • University of Arizona: PCOL 837B: Medicinal Chemistry III, 2 units, required second year course, 40 hours. VI. Courses Developed • University of California, Davis 2013 PHA 493: Special Studies Module (SSM) “Medical Genomics”,

4th year elective for MD students, developed by Segal and Herman. 2012 GGG 201C: Molecular Genetic Mechanisms of Disease, 4 units, required 2010 PHA 225: Gene Therapy, 3 units, elective for PhD students, co-developers Segal,

Anderson, Bauer, Nolta. 2007 PHA 250: Functional Genomics: From bench to bedside, 2 units, elective for PhD

students, co-developers Farnham, Diaz, Wright, and Segal. 2007 FRS 001: Freshman Seminar: Gene therapy: How genes control you and how you can

control them, 1 unit, elective for undergraduates. GRADUATE PROGRAM AFFILIATIONS: • University of California, Davis: 2013-2018 Molecular, Cellular and Integrative Physiology (MCIP) 2009-2017 Designated Emphasis in Translational Research (DETR) 2007-present Pharmacology and Toxicology Graduate Group (PTX) 2007-present Designated Emphasis in Biotechnology (DEB)


2005-present Biochemical and Molecular Biology Graduate Group (BMB) 2005-present Genetics Graduate Group (GGG) • University of Arizona: 2003-2005 Cancer Biology IDP 2002-2005 Biological Chemistry IDP 2002-2005 Pharmacology & Toxicology IDP 2002-2005 Medicinal Chemistry tract in Pharmaceutical Sciences 2002-2004 Toxicogenomics tract in Pharmaceutical Sciences STUDENT TRAINING: I. High School Students: • University of California, Davis: Rana Eser (2013) Davis High School Junior Internship with Natalie Grace Lara Schoen (2008) Davis High School Junior Internship Marquis Perkins (2007) Davis High School Senior Internship Becky Pacheco (2006) Davis High School Senior Internship – Currently attending UC Davis Vet School II. Undergraduate Students: • University of California, Davis: Isabelle Tankka (2017-present) Omar Karimi (2017-present) Emma Tilley (2017-present) Colleen Yi (2016-present) Sofie Bates (2016-present) Uche Onuchukwu (2016) Anna Adhikari (2016-2017) Ankita Singh (2016) Anvita Komarla (2015-2016) Koki Sasagawa (2015-2016) Victoria Le (2014-2016) Monica Hwu (2014-2015) Fernanda Ribas (2014) Rolando Del Pozo (2014) Joshua Mandella (2014) Lester Huynh (2013-2014) Danny Yu (2013) Joanna Watterson (2013-2015) Alexander Godbout (2013) Joelle Toney (2013) Shira Zats (2013) Peter Deng (2013-2014) – Currently graduate student, UC Davis (PTX). Patrick Lyon (2012-2013) Biotechnology – Currently graduate student, UCLA. Michelle McAlister (2012-2015) Biotechnology Alexa Adams (2012-2014) Biotechnology Jennifer Trang Nguyen (2012-2014) Work Study Student Robert Ovadia (2010-2012) Molecular Cellular Biology Mark Wallen (2009-2011) Biotechnology – PhD candidate at The Scripps Research Institute Alice Adriaenssens (2007-2009) Molecular Cellular Biology – PhD candidate at U. Cambridge. Geoffrey Lovely (2006-2007) Biochemistry – PhD candidate with David Baltimore at Cal Tech. • University of Arizona: Karen Louis (2005) Minority Health Disparities Program


Russell Means (2004) Biochemistry Student Volunteer Marlon Taylor (2004) Biochemistry Senior Project Rebecca Weiner (2003-2004) Biochemistry Senior Project Stacy Wood (2003-2004) Biochemistry Senior Project Benjamin Goot (2003-2004) Biology/Chemistry Student Volunteer III. Graduate Students: • University of California, Davis: Kevin De Leon (2016), MCIP Cody Polumbo (2014-present), Co-mentor Peter Beal, Chemical Biology Peter Deng (2014-present) Co-mentor Jan Nolta, PTX Simon “Jesse” Lopez (2014-present) Co-mentor Janine LaSalle, IGG Nicole Coggins (2014-present) Co-mentor Luis Carvajal-Carmona, MCIP Abigail Yu (2011-2015) Co-mentor Ian Korf, Genetics Graduate Group

PhD 2015 “A Bioinformatic Investigation of Off-Target Binding Events of Engineered DNA-Binding Proteins and Applications of Artificial Transcription Factors for Malaria Research” – Currently at Sutro Biopharma, Inc.

Josh Meckler (2009-2015) Biochemistry, Cell, Devel and Molecular Biology Graduate Group PhD 2015 “The Paradigm of Understanding, Engineering and Delivering DNA-Binding Proteins” – Currently post-doc at UC Davis.

Barbara Bailus (2008-2014) Genetics Graduate Group PhD 2013 “Towards Molecular Therapy for Angelman Syndrome Utilizing Artificial Transcription Factors” – Currently post-doc at Buck Institute for Research on Aging, CA.

Kumitaa Theva Das (2008-2014) Genetics Graduate Group PhD 2013 “Using Zinc Finger Nucleases (ZFN) to Permanently Inactivate HIV”

– Currently on faculty Universiti Sains Malaysia. Sarah Lockwood (2006-2012) Biochemistry and Molecular Biology Graduate Group PhD 2012 “Studies of Cys2His2 Zinc Finger Proteins and Their Roles in Biology and

Biotechnology” – Currently at Genentech, CA. Artem Zykovich (2005-2010) Co-mentor Ian Korf, Pharmacology and Toxicology Grad Group PhD 2010 “Developing Bind-n-Seq for Identification of C2H2 Zinc Fingers and Other

Proteins DNA Binding Properties” – Currently at Raptor Pharmaceuticals, CA. • University of Arizona: Mital Bhakta (2004-2012) Biological Chemistry IDP (Med Chem, home dept.) PhD 2012 “Highly Active Zinc Finger Nucleases by Extended Modular Assembly”

– Currently a Post-Doc with Michele Calos, Stanford Wendy Hartsock (2003-2005) Biological Chemistry IDP (Med Chem, home dept.)

MS 2005 “Uranyl acetate-induced inhibition of DNA-binding proteins” – PhD at U. Kansas, now at Biotage.

Kathryn “Charlie” Brayer (2002-2008) Toxicogenomics tract in Pharmaceutical Sciences PhD 2008 “The Protein Binding Potential of C2H2 Zinc Finger Domains” – Currently a Post-Doc with Günter Wagner at Yale University.

Will Taylor (2002-2004) Biological Chemistry IDP (Biochemistry, home dept.) MS 2004 “The design and preparation of polydactyl zinc finger proteins that will direct chimeric enzymes to specific target sites in HIV-1” – USC Dental School, Currently a dentist. Aik Teong Ooi (2002-2007) Biological Chemistry IDP (Med Chem, home dept.)

PhD 2007 “Sequence-Specific DNA Detection Utilizing Custom-Designed Zinc Finger Proteins” – Post-Doc with Brigitte Gomperts at UCLA, now at Fluidigm, CA.

IV. Laboratory Technicians: • University of California, Davis:


Sakereh Carter (2017-present) Vivian Yu (2017-present) Ruth Lee (2016) Julian Halmai (2014-2015) Peter Deng (2014) Natalie Grace (2012-2014) Ben Pyles (2010-present) Yuka Shimizu (2006-2008) – Currently a PhD candidate, U. Chicago. • University of Arizona: John Bennett (2004) Mary Teresa Lavin (2003) Ross Varga, Res. Tech. (2002-2003) – Currently a practicing Pharm.D in Flagstaff, AZ. V. Post-doctoral Fellows: • University of California, Davis: Antonio Gomez (2017-present) Ulrika Beitnere (2017-present) Mital Bhakta (2012-2014) – Currently a post-doc with Michele Calos, Stanford Sarah Lockwood (2012-2014) – Currently at Genentech, CA. Geeta Meher (2012-2013) Scot Lieser (2011-2012) Moon-soo Kim (2009-2012) – Faculty at Western Kentucky University Zhen Jia (2008-2010) Vincent Brondani (2005-2006) – Currently at EMBL Heidelberg, Germany VI. Project Scientists • University of California, Davis: Henriette O’Geen (2013-present) VII. Extramural Students: • University of California, Davis: Chonghua Ren (2014-2016) PhD candidate, Northwest A&F University, China. (2-year internship). Jesse Owens (2014) postdoctoral fellow, University of Hawaii, Manoa, (3-mo internship) Emiel ten Buren (2014) MS candidate at Wageningen University, the Netherlands. (6-mo internship) – Currently a PhD candidate in the Netherlands. Julian Halmai (2014) MS candidate at University of Groningen, the Netherlands. (6-mo internship) – Currently a PhD candidate at UC Davis. Sophie Cohen (2013) undergraduate at College of William and Mary, VA (2-mo internship). Yugo Hayashi (2013) PhD candidate at Nara Institute for Science and Technology, Japan, (2-mo internship). Mitchell O’Connell (2009, 2010) PhD candidate at University of Sydney, Australia. (3-mo internship) – Currently a post-doc at UC Berkeley with Jennifer Doudna. Sanjeev Kulshreshtha (2006) MS candidate at University of Texas, El Paso. (3-mo internship) • University of Arizona: Willemijn Gommans (2005) PhD candidate at Groningen University Institute for Drug Exploration, The Netherlands. (summer internship) VIII. Sabbatical Visitors: 2017-18 Xiuyan Shi, Shenyang Medical College, China 2016-17 Isabelle Marty, Grenoble Institut des Neurosciences, INSERM, France IX. Student Awards/Honors:


2018 Nicole Coggins. American Society for Gene and Cell Therapy travel award. 2018 Peter Deng. American Society for Gene and Cell Therapy oral presentation. 2018 Peter Deng. American Society for Gene and Cell Therapy travel award. 2018 Peter Deng. American Society for Neural Therapy and Repair travel award. 2018 Colleen Yi. 29th Undergraduate Research, Scholarship & Creative Activities, poster. 2018 Sofie Bates. 29th Undergraduate Research, Scholarship & Creative Activities, oral. 2018 Antonio Gomez. T32 Training Grant in Oncogenic Signals and Chromosome Biology. 2017 Peter Deng. Platform presentation at the 24th Annual Meeting of the ASNTR 2017 Peter Deng. American Society for Neural Therapy and Repair travel award. 2017-18 Nicole Coggins. Diversity Supplement 1R21CA204563. 2016 Nicole Coggins. Barbara Horwitz & John Horowitz MCIP Award. 2016 Kevin De Leon. MCB NIH T32 Training Grant Fellowship. 2016 Peter Deng. PTX NIH T32 Training Grant Fellowship. 2015 Peter Deng. Dake Foundation Fellowship. 2014 Nicole Coggins. MCB NIH T32 Training Grant Fellowship. 2014 Sarah Lockwood. DEB Internship at Genentech. 2014 Barbara Bailus. DEB Internship at Buck Institute. 2014 Abigail Yu. DEB Internship at Sutro Pharmaceuticals. 2012-13 Abigail Yu. UCD Biotechnology Fellowship. 2011 Scot Lieser. Two-year NGEC Postdoctoral Fellowship. 2010 Barbara Bailus. Three-year NSF Fellowship. 2009 Artem Zykovich. GSR Summer Research Award 2009 Barbara Bailus. Howard Hughes Research Institute Training Fellowship. 2009-13 Kumitaa Theva Das. Malaysian National Fellowship. 2009 Alice Adriaenssens. Four-year Gates Foundation Fellowship to attend U. Cambridge. 2007-08 Sarah Lockwood. UCD Biotechnology Fellowship. 2006 Sarah Lockwood. MCB NIH T32 Training Grant Fellowship. 2006 Becky Pacheco. Monsanto Award for High School Internship. 2006 Geoffrey Lovely. Summer internship at NIH. 2004 Aik Teong Ooi. Caldwell Award. 2004 Wendy Hartsock. Biological Chemistry Program Fellowship. 2004 Marlon Taylor. McNair Achievement Program Scholar. 2003-04 Kathryn “Charlie” Brayer. NSF Integrative Graduate Education and Research Traineeship (IGERT) in Evolutionary, Functional and Computational Genomics. 2003 Aik Teong Ooi. Biological Chemistry Program Fellowship. 2003 Aik Teong Ooi. Yuma Award. X. Qualifying Examination Committees: 2018 Xander Wilcox, Chemistry 2018 Lindsay Fague, BMCDB 2018 Luis Eduardo Conteres Llano, BMCDB 2018 Nichole Lewis, BMCDB, Chair 2017 Xiyuan Chang, PTX 2017 Maika Malig, IGG, Chair 2016 Linda Su, BMCDB, Chair 2016 Krishna Choudhary, Biomedical Engineering Graduate Group 2016 Ahmed Mahdi, Animal Science 2016 Mirko Leeda, IGG, Chair 2014 Anna Marie Tuazon, BMCDB Graduate Group, Chair 2014 Michelle Tjahjadi, IGG Masters Plan 2 2014 Hyun Tae Hwang, PTX Graduate Group 2014 Tingting Liu, MCIP Graduate Group


2014 Nicole Chaffee, Chemistry Graduate Group 2013 Christopher Beitel, Genetics Graduate Group, Chair 2013 Juan Reyes, Genetics Graduate Group 2012 Benjamin Yuen, BMCDB Graduate Group 2012 Phillip Seitzer, BME Graduate Group 2011 Matthew Grimmer, Genetics Graduate Group 2011 Ardian Coku, BMCDB Graduate Group 2011 Alexi Morris, Chemistry Graduate Group 2010 Erick Loomis, Genetics Graduate Group 2010 Jose Ibarra-Soza, Chemistry Graduate Group 2010 Weston Powell, MD/PhD 2010 Paul Ginno, GGG Graduate Group 2010 Rena Goodman, Chemistry Graduate Group 2009 Paul Lott, Genetics Graduate Group 2008 Kerry Masterson, Chemistry Graduate Group 2008 David Krawiec, PTX Graduate Group 2008 Kristina Mahn, BMB Graduate Group 2008 Hayden Peacock, Chemistry Graduate Group 2008 Paige McKibbin, Chemistry Graduate Group 2007 Sushma Iyengar, BMCDB Graduate Group 2006 Vitalina Komashko, PTX Graduate Group 2006 Franklin Chin, BMB Graduate Group XI. Ph.D. Dissertation Committees: • University of California, Davis: 2018-present Ruth Lee, (Jill Siverman, advisor), MCIP 2018-present Maika Malig, (Fred Chedin, advisor), IGG 2018-present Thomas Sears, (Kevin Woolard, advisor), PTX 2016-present Mirko Leeda, (Sharon Aviran, advisor), IGG 2016-present Linda Su-Feher (Alex Nord, advisor), BMCDB 2016-present Krishna Choudhary, (Sharon Aviran, advisor), BME 2016 Brittany Radke, (M.S., Megan Dennis, advisor) Forensics 2016 Priyanka Kulkarni, (M.S., Ian Korf, advisors) IGG 2016 Ravi Dandekar, (M.S., Alex Nord and Ian Korf, advisors), IGG 2014-2017 Priyanka Somanath, (Paul Knoepfler, advisor), BMCDB 2014-2016 Ruochuan Pan, (Janine LaSalle, advisor), IGG 2014-2017 Anna Marie Tuazon, (Luis Carvajal-Carmona, advisor), BMCDB 2014-present Jesse Lopez (Co-Chair with Janine LaSalle), IGG 2014-present Nicole Coggins (Co-Chair with Luis Carvajal-Carmona), MCIP 2014-present Peter Deng (Co-Chair with Jan Nolta), PTX 2014-present Marcela Vilarino, (Pablo Ross, advisor), Animal Biology 2014-2016 Nicole Chaffee, (Sheila David, advisor), Chemistry 2013-2016 Keith Dunaway, (Janine LaSalle, advisor), IGG 2013-2016 Stefanos Kalomoiris, (Jan Nolta, advisor), BMCDB 2012-2016 Benjamin Yuen, (Paul Knoepfler, advisor), BMCDB 2012-2015 Abigail Yu (Co-Chair with Ian Korf), Genetics 2011-2014 Adam Blattler (Peggy Farnham, advisor), BMCDB 2011-2014 Matthew Grimmer (Peggy Farnham, advisor), Genetics 2011-2013 Agnieszka Laskowski (Paul Knoepfler, advisor), BMCDB 2010-2015 Josh Meckler (Chair) BMCDB 2010-2013 Erick Loomis (Paul Hagerman, advisor), Genetics 2010-2013 Barbara Bailus (Chair) Genetics 2010-2013 Kumitaa Theva Das (Chair) Genetics


2010- 2013 Weston Powell (Janine LaSalle, advisor) MD/PhD 2010- 2013 Rena Goodman (Peter Beal, advisor) Chemistry 2010-2011 Haley Scoles (Janine LaSalle, advisor), Genetics Masters Student 2009-completeRoger Jesinghaus (Enoch Baldwin, advisor) Chemistry 2009-2013 Paul Lott (Ian Korf, advisor) Genetics 2009-2012 To “Mary” Uyen Do (Andrew Vaughan, advisor) Immunology 2008-2013 Sarah Lockwood (Chair) BMCDB 2008-2011 Sushma Iyengar (Peggy Farnham, advisor) BMB 2008-2010 Kimberly Blahnik (Peggy Farnham, advisor) BMB 2007-2010 Artem Zykovich (Co-Chair with Ian Korf) PTX 2007-2010 Vitalina Komashko (Peggy Farnham, advisor) PTX 2007-2010 Alina Rabinovich (Peggy Farnham, advisor) BMCDB 2007-2010 Franklin Chin (Earl Sawai, advisor) BMB • University of Arizona: 2004-2005 Hong Gao (Myron Jacobson, advisor) Pharmacology & Toxicology, PhD 2006 2004-2005 Kexiao Guo (Lawrence Hurley, advisor) Biological Chemistry 2004-2005 Jason Porter (Indraneel Ghosh, advisor) Biological Chemistry IDP 2004-2005 Haipeng Sun (Qin Chen, advisor) Pharmacology & Toxicology 2003-2005 Justin Crotty (Nancy Horton, advisor) Biological Chemistry 2003-2005 Clifford Stains (Indraneel Ghosh, advisor) Biological Chemistry, PhD 2008 2003-2005 Clifford Whatcott (Myron Jacobson, advisor) Medicinal and Natural Products

Chemistry 2003-2005 Ryan Wozniack (Bernard Futscher, advisor) Pharmacology & Toxicology 2002-2005 Laura Beer (Bradley Moore, advisor) Pharmacology & Toxicology, PhD 2006 2002-2004 Karolyn Richards (Daniel Liebler, advisor) Pharmaceutical Sciences, MS 2004 • Extramural Dissertation Committees: 2013 Jade Benjamin (Scott Dindot, advisor), Texas A&M University 2007 Fiona Loughlin (Joel Mackay, advisor), University of Sydney, Australia, PhD

awarded in 2007 2006 Willemijn Gommans (Marianne Rots, advisor), Groningen University, The

Netherlands, PhD awarded in 2006 INTELLECTUAL PROPERTY 2017 UC Case No. 2017-554-1 “Targetable factors that deposit H3K27me3 epigenetic marks”,

Inventors: Segal, O’Geen, Mackay, Farnham. Status: Active 2016 UC Case No. 2016-423 “Animal Model of Angelman Syndrome”, Inventors: Segal,

O’Geen, Pyles. Status: Active, Patent being sought. 2015 UC Case No. 2015-842-1 - Provisional Patent Application “Compositions and Methods

for Delivering Biotherapeutics”, Inventor: Pyles, Bailus, Deng, Lockwood, Segal. Status: Provisional Active

2011 UC Case No. 2012-226 “High-Throughput Screening of Transcriptional Protein Drugs”, Inventor: Segal. Status: Active.

2010 UC Case No. 2010-647 “Targetable nucleases using engineered TAL effector domains (TALNs)”, Inventors: Segal, Michelmore, Bhakta. Status: Abandoned.

2007 UC Case No. 2007-598 “Structure-Based Redesign of The Dimerization Interface of Zinc Finger Nucleases”, Inventors: Cathomen, Segal, Serrano. Status: Abandoned.

2007 UC Case No. 2007-082 “Correction of Genetic Mutations by Targeted Rearrangements Using Engineered Endonucleases”, Inventors: Segal, Camenisch, Brilliant. Status: Abandoned.


2006 US2009/068164 A1. “Sequence-Enabled Enzyme Reactivation (SEER) – A Novel Method for Visualizing Specific DNA Sequences”, Inventors: Segal, Ghosh, Ooi, Porter, Stains, Barbas. Status: Granted. Funding Source: University of Arizona.

2003 US 10/395,816 “Methods and compositions for using zinc finger endonucleases to enhance homologous recombination.” Inventors: Liljedahl, Aspland, Segal.

INVITED LECTURES: 1998 “Gene-specific transcriptional regulation using polydactyl zinc finger proteins

constructed from modular building blocks”, University of California, San Diego. 2001 “Novel zinc finger proteins for the therapeutic regulation and modification of genomes”,

University Kebangansan Malaysia, Pengumuman Seminar. 2001 “Novel zinc finger proteins for the therapeutic regulation and modification of genomes”,

Cold Spring Harbor Course on Protein Purification & Characterization. 2002 “Novel zinc finger proteins for the therapeutic regulation and modification of genomes”,

Kyoto University, Japan. 2002 “Endogenous Gene Regulation with Polydactyl Zinc Finger Transcription Factors”, 5th

Annual Meeting of the American Society of Gene Therapy, Boston, MA. 2002 “Novel zinc finger proteins for the therapeutic regulation and modification of genomes”,

University of Arizona, Tucson, Biological Chemistry Program. 2002 “Novel zinc finger proteins for the therapeutic regulation and modification of genomes”,

University of Arizona, Tucson, Animal Science. 2003 “Zinc Finger-Based Therapeutics for the Genome”, University Zurich-Irchel,

Switzerland. 2003 “Functional Genomics: A big picture of the new big science”, Phoenix Campus of

University Arizona Health Science Center. 2003 “Zinc Finger Therapeutics for the Genome”, University of Arizona, Tucson, Cancer

Biology Seminar. 2003 “Zinc Finger Therapeutics for the Genome”, University of Arizona, Tucson,

Pharmacology and Toxicology Seminar. 2003 “Zinc Finger Therapeutics for the Genome”, University of Arizona, Tucson,

Biochemistry and Molecular Biophysics. 2004 “Why did nature choose to encode 4500 zinc fingers in our genome?”, Northern Arizona

University, Arizona, NAU/AZCC Research Symposium 2004 “Zinc Finger-Based Therapeutics for the Genome”, Universita di Roma “La Sapienza”,

Italy. 2005 “Zinc Finger-Based Therapeutics for the Genome”, University of Arizona, Tucson,

Medicinal and Natural Products Chemistry. 2005 “Zinc Finger-Based Therapeutics for the Genome”, University of Arizona, Tucson,

Molecular and Cellular Biology. 2005 “Zinc Finger-Based Therapeutics for the Genome”, University of California, Davis,

Genome Center Colloquium, invited speaker. 2005 “Zinc Finger-Based Therapeutics for the Genome”, University of California, Davis,

MCB 220L Donut Talks. 2006 “Zinc Finger-Based Therapeutics for the Genome”, University of California, Davis,

Department of Animal Science. 2006 “Better Living Through Targeted Recombination”, University of California, Davis,

MIC 275, Seminar in DNA Repair and Recombination 2006 “Better Living Through Targeted Recombination”, University of California, Davis,

Department of Physiology. 2006 “Using SEER for the direct detection of double-stranded DNA sequence information”,

University of California, Davis, Center for Biophotonics Science and Technology. 2006 “Structural analysis of modularly assembled zinc fingers and their application in the

SEER diagnostic technology”, Sangamo Biosciences, Inc., Richmond, CA.


2006 “Better Living Through Targeted Recombination”, University of North Carolina, Chapel Hill, Dept. Pharmacology

2006 “Better Living Through Gene Correction by Targeted Recombination”, Mini-Symposium, Groningen University Institute for Drug Exploration, The Netherlands.

2007/3 “Better Living Through Gene Correction by Targeted Recombination”, University of California, Davis, Genome Center

2007/3 “Please help my zinc finger protein find a good home”, University of California, Davis, Epigenetics Club

2007/5 “Editing and imaging the genome”, University of California, Davis, Genome Center External Advisory Committee meeting

2007/8 “Editing and imaging genomes using engineering zinc finger proteins”, Transgenic Animal Research Conference VI, Granlibakken, Lake Tahoe, CA.

2007/10 “Critical parameters for genome editing using zinc finger nucleases”, University of California, Davis, Recombination and Repair Club

2007/10 “Editing and imaging genomes using engineered zinc finger proteins”, University of California, Davis, Department of Biomedical Engineering

2007/10 “Editing and imaging genomes using engineered zinc finger proteins”, Iowa State University, Dept. of Genetics, Development & Cell Biology

2008/2 “Editing and imaging genomes using engineered zinc finger proteins”, University of California, Davis, MIND Institute

2008/2 “Editing and imaging genomes using engineered zinc finger proteins”, University of California, Davis, Department of Environmental Toxicology

2008/5 “Sequence-Enabled Reassembly (SEER) for the detection of genetic information”, Inaugural Advances in Biodefense Technology conference, Barcelona, Spain

2008/6 “Editing and imaging genomes using engineered zinc finger proteins”, University of California, Davis, Cancer Center, Cancer Therapeutics Program Meeting

2008/10 “Editing and imaging genomes using engineered zinc finger proteins”, Children’s Hospital of Oakland Research Institute

2008/11 “Editing and imaging genomes using engineered zinc finger proteins”, University of California, Davis, T32 Training Program in Basic and Translational Cardiovascular Science Distinguished Speakers Seminar Series

2009/2 “Editing and imaging genomes using engineered zinc finger proteins”, Nara Institute of Science and Technology, Nara, Japan

2009/4 “Editing and imaging genomes using engineered zinc finger proteins”, University of California, Davis, Genome Center.

2009/7 “Towards Gene Therapy for Angelman Syndrome using Artificial Transcription Factors”, Angelman Syndrome Foundation, Orlando, FL

2009/10 “Protein microarrays for the capture of bacteria and identification of bacterial DNA”, 4th Annual UC Davis Research Retreat on Host Microbe Interaction, Granlibakken, Lake Tahoe, CA

2010/02 “A Novel Microdevice Employing Protein Microarray for Multiplexed Detection of Pathogens in Blood”, UC Davis Point-of-Care Technologies Center NIH Site Visit

2010/02 “Genome engineering for the masses: where is Henry Ford” UC Davis Recombination and Repair Club, Davis, CA.

2010/05 “Towards Gene Therapy for Angelman Syndrome”, fundraiser for Foundation for Angelman Syndrome Therapeutics, Auburn, CA.

2010/06 “Towards an Epigenetic Therapy for Rett Syndrome”, UC Davis CTSC Annual Retreat 2010/06 “Dissecting the genetic architecture of common diseases”, 1st FASEB conference on

Genome Engineering: Research and Therapeutic Applications, Steamboat Springs, CO. 2010/08 “Towards Gene Therapy for Angelman Syndrome”, Foundation for Angelman

Syndrome Therapeutics, Sydney, Australia. 2010/08 “Editing the genome with engineered DNA-binding proteins”, University of Sydney,

Department of Biochemistry and Microbiology, Sydney, Australia.


2010/10 “Editing the genome with engineered DNA-binding proteins”, 3° Congresso Brasileiro de Biotecnologia, Fortaleza, CE, Brazil. Plenary Speaker.

2010/11 “Programmable Nucleases for Engineering the Genomes of Stem Cells”, Wellcome Trust Advanced Course: Genetic Manipulation of ES Cells, Hinxton, UK.

2010/12 “From Engineering Proteins to Engineering Genomes and Epigenomes”, UC Davis Epigenomics Focus Group

2011/02 “A Novel Microdevice Employing Protein Microarray for Multiplexed Detection of Pathogens in Blood”, UC Davis Point-of-Care Technologies Center NIH Site Visit

2011/03 “From Engineering Proteins to Engineering Genomes and Epigenomes”, UC Davis Genome Center.

2011/05 “Creating nuclease disruptors of HIV activity”, UC Davis Department of Medical Microbiology and Immunology.

2011/06 “Dissecting the genetic architecture of common diseases by genome engineering”, Children’s Hospital of Oakland Research Institute, Oakland, CA.

2011/08 “A Zinc Finger Protein Array for the Visual Detection of Specific DNA Sequences for Diagnostic Applications”, 5th Ann Enabling Point-of-Care Diagnostics, Washington, DC.

2011/11 “Beyond GWAS: Next-gen nucleic acid binding proteins to study non-coding elements” International Conference of Genomics, Changchun, China.

2011/12 “Genetic Variation and Medicine” Genetics Case Conferences, UC Davis MIND Institute.

2012/02 “PIs and Mentors” External Advisory Board of the UC Davis Clinical and Translational Science Center.

2013/02 “Gene Activation Therapy for Angelman Syndrome” Foundation for Angelman Syndrome Therapeutics, Melbourne, Australia.

2013/07 “GAME-ON (Genetic Associations and Mechanisms in Oncology):7th Plenary Meeting”, NCI, Bethesda, MD. Plenary Speaker.

2013/09 “hiPSCs as the future of genomic research”, Stem Cell Research and Regenerative Medicine Retreat, University of California, Davis

2013/09 “ZFNs, TALENs, and CRISPRs for ASD research (and treatment?)”, Dup15q Alliance scientific meeting, University of California, Davis

2013/10 “Dissecting the genetic architecture of coronary artery disease”, UC Davis, T32 Training Program in Basic and Translational Cardiovascular Science Seminar Series

2013/10 “Engineered hiPSCs as the future of genomics research”, UC Davis, BGI@UC Davis Quarterly Seminar

2013/10 “Engineered hiPSCs as the future of genomics research”, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

2013/11 “Injectable Gene Activation Therapy for Angelman Syndrome”, UC Davis, MCIP Fall Colloquium

2013/12 “Injectable Gene Activation Therapy for Angelman Syndrome”, Foundation for Angelman Syndrome Therapeutics Global Summit, Chicago, IL

2014/1 “Injectable Gene Activation Therapy for Angelman Syndrome”, UC Davis, Center for Comparative Medicine Seminar Series

2014/2 “Injectable Gene Activation Therapy for Angelman Syndrome”, Waisman Center, Madison, WI.

2014/3 “Engineered hiPSCs as the future of genomics research”, UC Davis, MIC Seminar Series 2014/4 “How to use our genomes to improve public health”, Texas A&M University, College

Station, TX. 2014/5 “How to use our genomes to improve public health”, UC Davis, Cell and Development

Club. 2014/5 "Advanced targeting strategies for TALEs and CRISPRs", 17th Annual Meeting, American

Society of Gene and Cell Therapy, Washington, DC. 2014/6 “Injectable Gene Activation Therapy for Angelman Syndrome” Northern California

Genetics Exchange, Kaiser Vacaville Medical Facility, CA.


2014/8 “Zinc Finger-Based Therapeutics for the Genome”, Carlos F. Barbas, III, Memorial Symposium, The Scripps Research Institute, La Jolla, CA.

2014/9 “TALEs and CRISPRs to combat malaria”, Bay Area Malaria Meeting (BAMM), Zagaya, Emeryville, CA.

2014/9 “Engineered hiPSCs as the future of genomics research”, UCSF, Institute for Human Genetics seminar series, San Francisco, CA.

2014/9 “Injectable Gene Activation Therapy for Angelman Syndrome”, Neurology Grand Rounds, UC Davis, CA.

2014/10 “Engineered hiPSCs as the future of genomics research”, T32 Training Program in Basic and Translational Cardiovascular Science Seminar Series, UC Davis.

2014/10 “Genetics and genomics applications to medical breakthroughs”, 12th Annual UCDPHSA Pre-Medical & Pre-Health Professions National Conference, UC Davis.

2014/10 “Targeted reactivation of UBE3A in a mouse model of Angelman syndrome”, Colloque Scientifique International du Syndrome d'Angelman, Paris, France.

2014/10 “Genome Engineering at the Dawn of the Golden Age”, Northern California Society of Toxicology, UCSF, San Francisco, CA.

2014/11 “Genome Engineering at the Dawn of the Golden Age”, 3rd Annual Genome Center Symposium, UC Davis.

2014/11 “Genome Engineering at the Dawn of the Golden Age”, 13th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases, Sonoma, CA.

2014/12 “The Prospect of Molecular Therapy for Angelman Syndrome”, 2014 FAST Summit & Gala, Chicago, IL.

2015/02 “Injectable protein based gene activation therapy for PWS”, Prader-Willi Research Foundation Australia, Melbourne, Australia.

2015/02 “Injectable protein based gene activation therapy for PWS”, 3rd Asia-Pacific Prader-Willi Syndrome Conference, Melbourne, Australia.

2015/06 “Genome Engineering at the Dawn of the Golden Age”, Biotechnology and Bimolecular Sciences, U. New South Wales, Sydney, Australia.

2015/06 “Genome Engineering at Dawn”, Molecular Biosciences, U. Sydney, Sydney, Australia. 2015/10 “Targeted Reactivation of Ube3a in a Mouse Model of Angelman Syndrome”,

Organizzazione Sindrome Di Angelman, Assisi, Italy. 2015/11 “Genome Engineering at the Dawn of the Golden Age”, 6° Congresso da Sociedade

Brasileira de Biotecnologia, Brasilia, Brazil. 2015/12 “Reactivation of Ube3a as therapy”, 2015 FAST Summit & Gala, Chicago, IL. 2016/03 “Biomarkers, Year 3 update, Year 4 plan, New Project”, 2015 FAST Summit, Tampa, FL. 2016/05 “Protein Delivery of an Artificial Transcription Factor Restores Widespread Ube3a

Expression in an Angelman Syndrome Mouse Brain” ASGCT, Washington, DC. 2016/05 “Genome Engineering with CRISPR/Cas9 at the Dawn of the Golden Age” Radiation

Oncology Grand Rounds, UC Davis Cancer Center. 2016/06 “Genetic and Epigenetic Engineering in Cancer Research” NIH-NCI, Bethesda, MD. 2016/07 “Protein Delivery of an Artificial Transcription Factor Restores Widespread Ube3a

Expression in an Angelman Syndrome Mouse Brain” Angelman Syndrome Foundation, Silver Spring, MD.

2016/09 “How to cure Angelman Syndrome in two years” Neurology Grand Rounds, UC Davis 2016/10 “Genome Engineering with CRISPR/Cas9 at the Dawn of the Golden Age” 2016

Microsomes and Drug Oxidations (MDO), UC Davis, CA. 2016/11 Webinar: “Methods for validating a gene editing approach to treating brain disease

with zinc fingers, TALEs, and CRISPR/Cas9” Current Protocols with MilliporeSigma. 2016/12 “ATF and ASO AS therapy”, 2016 FAST Summit & Gala, Chicago, IL. 2017/03 “FIRE Year 4 update: ATF therapy” FAST In-Person Annual Meeting, UC Davis, CA. 2017/03 “Artificial Transcription Factor Therapy Restores Ube3a Expression in an Angelman

Syndrome Mouse Brain”, University of Hawaii.


2017/05 "Targetable Epigenome Editing with dCas9/CRISPR” Chemical Biology Innovation Group (CBIG), UC Davis, CA.

2017/05 “Artificial Transcription Factor Therapy Restores Ube3a Expression in an Angelman Syndrome Mouse Brain”, ShanghaiTech University, SIAIS, Shanghai, China.

PUBLISHED ABSTRACTS: 1993 Keystone Symposium, Keystone, CO, on Genetically Targeted Research & Therapeutics:

Antisense & Gene Therapy. 1995 FASEB Summer Conference, Snowmass, CO, on Genetics Recombination and Genome

Rearrangements. 1998 Cold Spring Harbor Symposium, Cold Spring Harbor, NY, on Mechanisms of

Transcription. 1999 Keystone Symposium, Keystone, CO, on Molecular and Cellular Biology of Gene

Therapy. 2000 14th Annual Symposium of the Protein Society, San Diego, CA. 2001 Keystone Symposium, Keystone, CO, on HIV Pathogenesis. 2002 5th Annual Meeting of the American Society of Gene Therapy, Boston, MA. 2004 Keystone Symposium, Whistler, BC, on Molecular Mechanisms of HIV Pathogenesis 2004 8th International Conference on Malignancies in AIDS and Other Immunodeficiences,

NCI, Bethesda, MD 2005 8th Annual Meeting of the American Society of Gene Therapy, St. Louis, MO. 2005 19th Annual Symposium of The Protein Society, Boston, MA. 2005 Moving Biosensors to Point-of-Care Cancer Diagnostics, Rockville, MD. 2005 230th American Chemical Society National Meeting, Washington, DC. 2005 18th Symposium of the American Peptide Society, San Diego, CA. 2005 9th International Conference on Malignancies and Other Acquired Immunodeficiencies,

North Bethesda, MD. 2006 45th Annual Meeting of the Society of Toxicology, San Diego, CA. 2006 9th Annual Meeting of the American Society of Gene Therapy, Baltimore, MD.

2 abstracts. 2006 232nd American Chemical Society National Meeting, San Francisco, CA. 2 abstracts. 2006 19th Rocky Mountain Regional Meeting of the American Chemical Society, Tucson, AZ.

3 abstracts. 2006 20th Annual Symposium of The Protein Society, San Diego, CA. 2006 14th Annual Congress of the European Society of Gene Therapy, Athens, Greece. 2006 Annual Biomedical Research Conference for Minority Students (ABRCMS), Anaheim,

CA. 2007 10th Annual Meeting of the American Society of Gene Therapy, Seattle, WA.

2 abstracts. 2007 21th Symposium of the American Protein Society, Boston, MA. 2007 Transgenic Animal Research Conference VI, Granlibakken, Lake Tahoe, CA. 2008 Advances in Biodefense Technology, Barcelona, Spain 2008 11th Annual Meeting of the American Society of Gene Therapy, Boston, MA. 2009 12th Annual Meeting of the American Society of Gene Therapy, San Diego, CA. 2009 Angelman Syndrome Foundation Conference, Orlando, FL. 2009 “The Biology of Genomes”, CSHL meeting, Cold Spring Harbor, NY. 2009 4th Annual UC Davis Research Retreat on Host Microbe Interaction, Granlibakken, Lake

Tahoe, CA. 2010 8th Annual Meeting of the Int’l Society for Stem Cell Research, San Francisco, CA. 2010 Angelman Treatment and Research Institute Scientific Symposium, Chapel Hill, NC.


2010 1st FASEB conference on Genome Engineering: Research and Therapeutic Applications, Steamboat Springs, CO. 3 abstracts.

2010 2nd Annual Next-Generation Sequencing and Data Analysis, Providence, RI. 2010 Enabling Point-of-Care Diagnostics, Washington DC. 2010 Northwest Genome Engineering Consortium Workshop, Seattle, WA 2011 Functional Consequences of Structural Variation in the Genome, Keystone Symposium,

Steamboat Springs, CO. 2011 12th Annual IRSF Rett Syndrome Symposium, Leesburg, VA. 2011 Angelman Treatment and Research Institute's Scientific Symposium, Salt Lake City, UT. 2011 5th Annual Enabling Point-of-Care Diagnostics, Washington, DC. 2012 XVI International Symposium on Atherosclerosis, Sydney, Australia. 2012 Angelman Syndrome Foundation Conference, Rockville, MD. 2012 ISSCR Roddenberry Int’l Symposium on Cellular Reprogramming, San Francisco, CA. 2012 American Society for Human Genetics, San Francisco, CA. 2012 2nd FASEB conference on Genome Engineering: Research & Applications, Lucca, Barga,

Italy. 2013 International Meeting for Autism Research, San Sebastian, Spain. 2013 Precision Genome Engineering and Synthetic Biology: Designing Genomes and

Pathways, Keystone Symposium, Breckenridge, CO. 2013 Children’s Tumor Foundation Annual Conference, Monterey Bay, CA. 2014 17th Annual Meeting, American Society of Gene and Cell Therapy, Washington, DC. 2016 19th Annual Meeting, American Society of Gene and Cell Therapy, Washington, DC. 2016 46° Annual Meeting, Society for Neuroscience, San Diego, CA. 2017 50th Winter Conference on Brain Research, Big Sky, MT. 2017 Keystone Symposia Conference A2: Precision Genome Engineering, Breckenridge, CO. 2017 20th Annual Meeting, American Society of Gene and Cell Therapy, Washington, DC. 2017 24th Ann Mtg of the Am Society for Neural Therapy and Repair, Clearwater Beach, FL. 2017 CRISPR: From Biology to Technology and Novel Therapeutics, Sitges, Spain. 2017 47° Annual Meeting, Society for Neuroscience, San Diego, CA.

RESEARCH PUBLICATIONS: I. Books, Chapters, Commentaries and Non-Peer-Reviewed: 1. Ooi, A.T., Stains, C.I., Porter, J., Ghosh, I., & Segal, D.J. (2006) “Sequence-Enabled

Reassembly (SEER) Peptides for the Detection of DNA Sequences” in Understanding Biology Using Peptides, Sylvie E. Blondelle, editor, Springer, publisher, pp 214-215.

2. Segal, D.J. (2008) The ‘cutting edge’ of gene therapy…literally. The Biochemist. June:10-13. Non-peer-reviewed review.

3. “Engineered Zinc Fingers: Methods and Protocols”, (2010) vol 649 in the series Methods in Molecular Biology, Human Press (editors Joel P. Mackay and David J. Segal).

Over 10,000 internet downloads from this book, top 25% of eBooks (Springer 2013). 4. Segal, D.J. (2011) Zinc-finger nucleases transition to the CoDA. Nat Methods. 8:53-55. 5. Segal, D.J. (2012) Beyond the genome and into the clinic. Genome Med. 4:78. 6. Segal, D.J. (2013) Bacteria herald a new era of gene editing. eLife, 2:e00563. 7. Vilarino, M, Meckler, J, Segal, DJ, Ross, JP 2016 (2016) Activation of pluripotency genes using

CRISPR/dCas9 system. Abstracts from the UC Davis Transgenic Animal Research Conference X (TARC X) Transgenic Research, Volume 25, pp 101-122.

II. Peer-reviewed publications


1. Segal, D.J. & Carroll, D. (1995) Endonuclease-induced, targeted homologous extrachromosomal recombination in Xenopus oocytes. Proc. Natl. Acad. Sci. U. S. A., 92, 806-810.

2. Faruqi, A.F., Seidman, M.M., Segal, D.J., Carroll, D. & Glazer, P.M. (1996) Recombination induced by triple-helix-targeted DNA damage in mammalian cells. Mol. Cell. Biol., 16, 6820-6828.

3. Segal, D.J., Faruqi, A.F., Glazer, P.M. & Carroll, D. (1997) Processing of targeted psoralen cross-links in Xenopus oocytes. Mol. Cell. Biol., 17, 6645-6652.

4. Liu, Q., Segal, D.J., Ghiara, J.B. & Barbas III, C.F. (1997) Design of polydactyl zinc-finger proteins for unique addressing within complex genomes. Proc. Natl. Acad. Sci. U. S. A., 94, 5525-5530.

5. Carroll, D. & Segal, D.J. (1998) Induced recombination in model systems. Curr. Res. Mol. Ther., 1, 593-598.

6. Beerli, R.R., Segal, D.J., Dreier, B. & Barbas III, C.F. (1998) Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc. Natl. Acad. Sci. U. S. A., 95, 14628-14633.

7. Segal, D.J., Dreier, B., Beerli, R.R. & Barbas III, C.F. (1999) Toward controlling gene expression at will: selection and design of zinc finger domains recognizing each of the 5'-GNN-3' DNA target sequences. Proc. Natl. Acad. Sci. U. S. A., 96, 2758-2763. Times Cited = 235 (2013 ISI).

8. Segal, D.J., & Barbas III, C.F. (2000) Design of novel sequence specific DNA-binding proteins. Curr. Opin. Chem. Biol., 4, 34-9.

9. Dreier, B., Segal, D.J., & Barbas III, C.F. (2000) Insights into the molecular recognition of the 5'-GNN-3' family of DNA sequences by zinc-finger domains. J. Mol. Biol., 303, 489-502. BD and DJS contributed equally to this work.

10. Bibikova, M., Carroll, D., Segal, D.J., Trautman, J.K., Smith J., Kim Y.-G., & Chandrasegaran, S. (2001) Stimulation of Homologous Recombination Through Targeted Cleavage by a Chimeric Nuclease. Mol. Cell. Biol., 21:289-297. Times Cited = 169 (2013 ISI).

11. Barbas III, C.F.., List, B., Rader, C., Segal, D.J., & Turner, J.M. (2000) “From Catalytic Asymmetric Synthesis to the Transcriptional Regulation of Genes: In Vivo and In Vitro Evolution of Proteins”, in Adv. Protein Chem., 55:317-366.

12. Dreier, B., Beerli, R.R., Segal, D.J., Flippin, J.D., & Barbas III, C.F.,. (2001) Development of zinc finger domains for recognition of the 5’-ANN-3’ family of DNA sequences and their use in the construction of artificial transcription factors. J. Biol. Chem. 276, 29466-29478.

13. Segal, D.J. & Barbas III, C.F.,. (2001) Custom DNA-binding proteins come of age: polydactyl zinc finger proteins. Curr. Opin. Biotech, 12, 632-637. Review.

14. Segal, D.J. (2002) The use of zinc finger peptides to study the role of specific factor binding sites in the chromatin environment. Methods, 26, 76-83.

15. Segal, D.J., Beerli, R.R., Blancafort, P., Dreier, B., Effertz, K., Huber, A., Koksch, B., Lund, C., Magnenat, L., Valente, D., & Barbas III, C.F.,. (2003) Evaluation of the modular approach in the design of novel zinc finger DNA-binding proteins. Biochemistry 42, 2137-2148.

16. Segal, D.J., Stege, J.T., & Barbas III, C.F., (2003) Zinc finger and a green thumb: manipulating gene expression in plants. Curr. Opin. Plant Biol. 6, 163-168. Review.

17. Tan, W., Zhu, K, Segal, D.J., Barbas III, C.F., & Chow, S.A. (2004) Fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc finger protein E2C direct integration of viral DNA into specific sites. J. Viorol. 78, 1301-1313.

18. Segal, D.J., Gonçalves, J., Eberhardy, S., Swan, C.H., Torbett, B.E., Li, X., & Barbas III, C.F. (2004) Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor. J. Biol. Chem. 279, 14509-14519.


19. Blancafort, P., Segal, D.J., & Barbas III, C. F. (2004) Designing transcription factor architectures for drug discovery. Mol. Pharm. 66, 1361-1371. Review

20. Coates, C.J., Kaminski, J.M., Summers, J.B., Segal, D.J., Miller, A.D., & Kolb, A.F. (2005) Site-directed genome modification: derivatives of DNA modifying enzymes as targeting tools. Trends in Biotech. 23:407-419. Review

21. Kolb, A.F., Coates, C.J., Kaminski, J.M., Summers, J.B., Miller, A.D., & Segal, D.J. (2005) Site-directed genome modification: nucleic acid and protein modules for targeted integration and gene correction. Trends in Biotech. 23: 399-406. Review

22. Alwin, S., Gere, M.B., Guhl, E., Effertz, K., Barbas III, C.F., Segal, D.J., Weitzman, M.D., & Cathomen, T. (2005) Custom zinc-finger nucleases for use in human cells. Mol. Therapy, 12:610-617.

23. Crotty, J., Etzkorn, C., Barbas III, C.F., Segal, D.J., & Horton, N.C. (2005) Crystallization and Preliminary X-Ray Crystallographic Analysis of Aart, a Designed Six-Finger Zinc Finger Peptide, bound to DNA. Acta Cryst. F61:573-576.

24. Stains, C.I., Porter, J., Ooi, A.T., Segal, D.J., & Ghosh, I. (2005) DNA sequence-enabled reassembly of the green fluorescent protein. J. Am. Chem. Soc. 127:10783-10783. Highlighted in “DNA makes GFP shine”, 2005, Nat Methods, 2:644

“Recommended” by the Faculty of 1000 25. Dreier, B., Fuller, R.P., Segal, D.J., Lund, C., Blancafort, P., Huber, A., Koksch, B. & Barbas

III, C.F. (2005) Development of zinc finger domains for recognition of the 5'-CNN-3' family DNA sequences and their use in the construction of artificial transcription factors J. Biol. Chem., 280:35588-35597.

26. Eberhardy, S., Gonçalves, J., Coelho, S., Segal, D.J., Berkhout, B. & Barbas III, C.F. (2006) Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site. J.Virology. 80:2873-2883.

27. Ooi, A.T., Stains, C.I., Ghosh, I., & Segal, D.J. (2006) SEquence-Enabled Reassembly of β-Lactamase (SEER-LAC): a Sensitive Method for the Detection of Double-Stranded DNA. Biochemistry, 45:3620-3625. (PMC2688710)

Highlighted in “Tech News”, 2007, BioTechniques, 42:131-135. 28. Stains, C.I., Segal, D.J., Ghosh, I. (2006) Site Specific Detection of DNA Methylation

Utilizing mCpG-SEER. J. Am. Chem. Soc, 128, 9761-9765. 29. Segal, D.J., Crotty, J., Bhakta, M., Barbas III, C.F., & Horton, N.C. (2006) Structure of Aart, a

Designed Six-Finger Zinc Finger Peptide, bound to DNA. J. Mol. Biol, 363:405-412. 30. Ghosh, I., Stains, C.I., Ooi, A.T., & Segal, D.J. (2006) Direct detection of double-stranded

DNA: molecular methods and applications for DNA diagnostics. Mol. BioSystems, 2:551-560. Review. Highlighted in “Engineered fingers spot mistakes in DNA”, 2006, Chem Biol, 12.

31. Carroll, D., Morton, J.J., Beumer, K.J. & Segal, D.J. (2006) Construction and Testing of Zinc Finger Nucleases. Nat. Protocols, 1:1329-1341.

32. Gommans, W.M., McLaughlin, P.M.J, Lindhout, B.I., Segal, D.J., Haisma, H.J, van der Zaal, B.J., & Rots, M.G. (2006) Engineering zinc finger protein transcription factors to down-regulate the epithelial glycoprotein-2 promoter as a novel anti-cancer treatment. Mol. Carcinogenesis, 46:391-401.

33. Shinohara, E.T., Kaminski, J.M., Segal, D.J., Pelczar, P., Kolhe, R., Coates, C.J., Ryan, T., Yanagimachi, R., and Moisyadi, S. (2007) Active Integration: New Strategies for Transgenesis. Transgenic Res., 16:333-339.

34. Hartsock, W.J., Cohen, J., and Segal, D.J. (2007) Uranyl acetate as a direct inhibitor of DNA-binding proteins. Chem. Res. Toxicol., 20:784-789.

35. Szczepek, M., Brondani, V., Büchel, J., Serrano, L., Segal, D.J. and Cathomen, T. (2007) Structure-based redesign of the dimerization interface reduces the toxicity of zinc finger nucleases. Nat. Biotechnol., 25:786-793. Times Cited = 162 (2013 ISI).


36. Porter, J.R., Stains, C.I., Segal, D.J., and Ghosh, I. (2007) Split beta-lactamase sensor for the sequence specific detection of DNA methylation. Anal. Chem., 79:6702-6708.

37. Camenisch, T.C., Brilliant, M.H., and Segal, D.J. (2008) Critical parameters for genome editing using zinc finger nucleases. Mini. Rev. Med. Chem., 8:669-676. Review.

38. Cathomen, T., Segal, D.J., Brondani, V. and Müller-Lerch, F. (2008) Generation and functional analysis of zinc finger nucleases. Methods Mol. Biol., 434:277-290.

39. Brayer, K.J., and Segal, D.J. (2008) Keep your fingers off my DNA – protein-protein interactions mediated by C2H2 zinc finger domains. Cell Biochem. Biophys., 50:111-131. Review.

40. Brayer, K.J., Kulshreshtha, S., and Segal, D.J. (2008) The protein binding potential of C2H2 zinc finger domains. Cell Biochem. Biophys., 51:9-19.

41. Furman, J.L., Badran, A.H., Stains, C.I., Shen, S., Hannallah, J., Jester, B.W., Segal, D.J., and Ghosh, I. (2009) Exploring split-fluorescent proteins for the direct detection of native and methylated DNA. Bioorg Med. Chem. Lett., 19:3748-3751. “Recommended” by the Faculty of 1000.

42. Shimizu, Y., Bhakta, M.S., and Segal, D.J. (2009) Restricted spacer tolerance of a zinc finger nuclease with a six amino acid linker. Bioorg Med Chem Lett., 19:3970-3972. (PMC2709702)

43. Zykovich, A., Korf, I. and Segal, D.J. (2009) Bind-n-Seq: high-throughput analysis of in vitro protein-DNA interactions using massively parallel sequencing. Nucleic Acids Res. 37:e151. (PMC2794170)

44. Bhakta, M. & Segal, D.J. (2010) The generation of zinc-finger proteins by modular assembly. Methods Mol. Biol., 649:3-30.

45. Porter, J., Lockwood, S., Segal, D.J. & Ghosh, I. (2010) Seeing genetic and epigenetic information without DNA denaturation using sequence enabled reassembly (SEER). Methods Mol. Biol., 649:365-382.

46. Furman, J. L., Badran, A. H., Ajulo, O., Porter, J. R., Stains, C. I., Segal, D. J., and Ghosh, I. (2010) Toward a General Approach for RNA-Templated Hierarchical Assembly of Split-Proteins, J Am Chem Soc. 132:11692-11701.

47. Kim, M.-S., Stybayeva, G., Lee, J.Y., Revzin, A., and Segal, D.J. (2011) A zinc finger protein array for the visual detection of pathogen-specific DNA sequences. Nucleic Acids Res. 39:e29.

48. Mackay, J.P., Font, J., and Segal, D.J. (2011) The prospects for designer single-stranded RNA-binding proteins. Nature Struct Mol Biol, 18:256-261 Review.

49. Shimizu, Y., Şöllü, C., Meckler, J. M., Adriaenssens, A., Zykovich, A., Cathomen, T., and Segal, D.J. (2011) Adding Fingers To An Engineered Zinc Finger Nuclease Can Reduce Activity. Biochemistry, 50:5033-5041. “Recommended” by the Faculty of 1000.

50. Owens, J.B., Urschitz, J., Stoytchev, I., Dang, N.C., Stoytcheva, Z., Belcaid, M., Maragathavally, K.I., Coates, C.J., Segal, D.J., and Moisyadi, S. (2012) Chimeric piggyBac Transposases for Genomic Targeting in Human Cells. Nucleic Acids Res, 40:6978-6991.

51. O’Connell, M.R., Vandevenne, M., Nguyen, C.D., Mathews, J., Gamsjaeger, R., Segal, D.J., and Mackay, J.P. (2012) Modular assembly of RanBP2-type zinc finger domains to target single-stranded RNA. Angewandte Chemie, 51:5371-5375

52. Meier, J.L., Yu, A., Korf, I., Segal, D.J. and Dervan, P.B. (2012) Guiding the Design of Synthetic DNA-Binding Molecules with Massively Parallel Sequencing, J Am Chem Soc. 134:17814-17822.

53. Bhakta, M.S., Henry, I.M., Ousterout, D.G., Theva Das, K., Lockwood, S.H., Meckler, J.F., Wallen, M.C., Zykovich, A., Yu, Y., Leo, H., Xu, L., Gersbach, C.A. and Segal, D.J. (2013) Highly Active Zinc-Finger Nucleases by Extended Modular Assembly, Genome Research, 23:530-538.

54. Meckler, J.F., Bhakta, M.S., Kim, M-S., Ovadia, R., Habrian, C.H., Zykovich, A., Yu, A., Lockwood, S.H., Morbitzer, R., Elsäesser, J., Lahaye, T., Segal, D.J., and Baldwin, E.P.


(2013) Quantitative Analysis of TALE-DNA Interactions Suggests Polarity Effects, Nucleic Acids Res, 41:4118-4128.

Featured Article, representing the top 5% of papers in the journal in terms of originality, significance and scientific excellence.

55. Vandevenne, M., Jacques, D.A., Artuz, C., Nguyen, C.D., Kwan, A.H., Segal, D.J., Matthews, J.M., Crossley, M., Guss, J.M., Mackay, J.P. (2013) New insights into DNA recognition by zinc fingers revealed by structural analysis of ZNF217. J Biol Chem. 288:10616-10627.

56. Segal, D.J. and Meckler, J.F., (2013) Genome Engineering at the Dawn of the Golden Age, Annu. Rev. Genomics Hum. Genet, 14:135–158.

57. Mackay, J.P., Segal, D.J., and Crossley, M. (2013) Is there a telltale RH fingerprint in zinc fingers that recognize methylated CpG dinucleotides? Trends Biochem Sci, 38:423.

58. Owens, J.B., Mauro, D., Stoytchev, I., Bhakta, M.S., Kim, M.-S., Segal, D.J. and Moisyadi, S. (2013) Transcription activator like effector (TALE) directed piggyBac transposition in human cells. Nucleic Acids Res, 41:9197-9207. (PMID: 23921635)

59. Johnson, L.M., Du, J., Hale, C.J., Bischof, S, Feng, S., Chodavarapu, R.K., Zhong, X., Marson, G., Pellegrini, M., Segal, D.J., Patel, D.J., Jacobsen, S.E. (2014) SRA/SET domain-containing proteins link RNA polymerase V occupancy to DNA methylation. Nature, 507:124-128.

60. Lei, H., Sun, J., Baldwin, E.P., Segal, D.J., Duan, Y. (2014) Conformational Elasticity can Facilitate TALE-DNA Recognition. Adv Protein Chem Struct Biol, 94:347-364

61. Barrilleaux, B., Burow, D., Lockwood, S., Yu, A., Segal, D.J., Knoepfler, P. (2014) Miz-1 activates gene expression via a novel consensus DNA binding motif. PLoS One. 9:e101151.

62. Lockwood, S.H., Guan, A., Yu, A.S., Zhang, C., Zykovich, A., Korf, I., Rannala, B., Segal, D.J. (2014) The Functional Significance of Common Polymorphisms in Zinc Finger Transcription Factors. G3, pii: g3.114.012195.

63. Vandevenne, M., O’Connell, M.R., Helder, S., Shepherd, N., M. Matthews, J.M., Kwan, A.H., Segal, D.J., and Mackay, J.P. (2014) Engineering Specificity Changes on a RanBP2 Zinc Finger that binds single-stranded RNA. Angew Chem Int Ed, 53:7848-7852.

64. Bailus, B.J., Segal, D.J. (2014) The Prospect of Molecular Therapy for Angelman Syndrome and Other Autism Spectrum Disorders. BMC Neurosci, 15:76.

65. Rader, C., Segal, D.J., Shabat, D. (2014) Carlos F. Barbas III (1964-2014): Visionary at the Interface of Chemistry and Biology. ACS Chem Biol. 9:1645-1646.

66. O'Geen, H., Henry, I.M., Bhakta, M.S., Meckler, J.F., Segal, D.J. (2015) A genome-wide analysis of Cas9 binding specificity using ChIP-seq and targeted sequence capture. Nucleic Acids Res. 43:3389-3404.

67. Frank, A.K., Tran, D.C., Qu, R.W., Stohr, B.A., Segal, D.J., Xu, L. (2015) The Shelterin TIN2 Subunit Mediates Recruitment of Telomerase to Telomeres. PLoS Genet, 11:e1005410.

68. O’Geen, H., Yu, A.S., and Segal, D.J. (2015) How specific is CRISPR/Cas9 really? Current Opinions in Chemical Biology. 29:72–78.

69. Tak, Y.G., Hung, Y., Yao, L., Grimmer, M.R., Do, A., Bhakta, M.S., O'Geen, H., Segal, D.J., Farnham, P.J. (2016) Effects on the transcriptome upon deletion of distal elements are not correlated with the size of H3K27Ac peaks in human cells. Nucleic Acids Res. pii: gkv1530.

70. Bailus, B.J., Pyles, B., McAlister, M.M., O’Geen, H., Lockwood, S.H., Adams, A.A., Trang Nguyen J.T., Berman R.F., and Segal, D.J. (2016) Protein Delivery of an Artificial Transcription Factor Restores Widespread Ube3a Expression in an Angelman Syndrome Mouse Brain. Mol Ther. 24:548-555.

71. Fink KD, Deng P, Gutierrez J, Anderson JS, Torrest A, Komarla A., Kalomoiris S, Cary W, Anderson JD, Gruenloh W, Duffy A, Tempkin T, Wheelock V, Segal DJ, and Nolta, JA. (2016) Allele-specific reduction of the mutant huntingtin allele using transcription activator-like effectors in human Huntington’s disease fibroblasts. Cell Transplant. 25:677-686.


72. O'Geen H, Ren C, Nicolet CM, Perez AA, Halmai J, Le VM, Mackay JP, Farnham PJ, and Segal DJ. (2017) dCas9-based epigenome editing suggests acquisition of histone methylation is not sufficient for target gene repression. Nucleic Acids Res, 45:9901-9916.

73. Lopez SJ, Dunaway K, Islam MS, Mordaunt C, Ciernia AV, Meguro-Horike M, Horike SI, Segal DJ, LaSalle J. (2017) UBE3A-mediated regulation of imprinted genes and epigenome-wide marks in human neurons. Epigenetics. 19:0. DOI: 10.1080/15592294.2017.1376151.

74. De Leon, K.J., Antrobus, S., Allen, P.D., Marty. I., Segal, D. (2017) A Method for Validating Mutations Associated with Malignant Hyperthermia using CRISPR/Cas9 and Dual Integrase Cassette Exchange. Biophysical J. 112:98a.

75. Coggins, N.B., Stultz, J., O’Geen, H, Carvajal-Carmona, L.G., Segal, D.J. (2017) Methods for Scarless, Selection-Free Generation of Human Cells and Allele-Specific Functional Analysis of Disease-Associated SNPs and Variants of Uncertain Significance. Sci Rep. 7:15044.

76. Gallego-Bartolomé J, Gardiner J, Liu W, Papikian A, Ghoshal B, Kuo HY, Zhao JM, Segal DJ, Jacobsen SE. (2018) Targeted DNA demethylation of the Arabidopsis genome using the human TET1 catalytic domain. Proc Natl Acad Sci U S A. 115:E2125-E2134. PubMed Central PMCID: PMC5834696.

77. Pyles B, Bailus BJ, O'Geen H, Segal DJ. (2018) Purified Protein Delivery to Activate an Epigenetically Silenced Allele in Mouse Brain. Methods Mol Biol. 1767:227-239. PubMed PMID: 29524138.

78. O’Geen, H, Ren, C., Coggins, N.B., Bates, S.L., and Segal, D.J. (2018) Unexpected binding behaviors of bacterial Argonautes in human cells cast doubts on their use as targetable gene regulators. PLoS ONE. 13:e0193818. PMID: 29584750.

.

segal cv 18 - biology.ucdavis.edu · the major goal of this project is to develop a therapy for...

Documents